Severe topiramate-associated hyperthermia resulting in persistent neurological dysfunction.

Area of Science:

• Neurology
• Pharmacology
• Thermoregulation

Background:

• Topiramate is an anticonvulsant and migraine prophylactic medication.
• Oligohydrosis and hyperthermia have been reported as adverse effects, primarily in pediatric populations.
• Previous cases were generally mild with no lasting systemic or neurological deficits.

Observation:

• A case of severe hyperthermia in an adult patient treated with topiramate is presented.
• The patient developed ataxia and tremor following the hyperthermic event.
• This represents a significant deviation from previously reported topiramate-associated hyperthermia cases.

Findings:

• The adult patient experienced severe hyperthermia and subsequent neurological impairment.
• Residual cerebellar dysfunction and cognitive deficits were observed post-event.
• This is the first documented instance of topiramate-induced hyperthermia leading to persistent neurological sequelae.

Implications:

• Topiramate-associated hyperthermia can lead to severe, lasting neurological complications in adults.
• Clinicians should be vigilant for signs of hyperthermia and neurological dysfunction in adult patients on topiramate.
• Further research is warranted to understand the mechanisms and risk factors for severe topiramate-induced hyperthermia in adults.